Market research
OKUR OnKure Therapeutics, Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 158M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- Not available
- Beta
- Not available
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US68277Q1058
- Market cap
- 158M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- Not available
- Beta
- Not available
About
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the OKUR discussion.
No comments yet
Start a focused discussion about OKUR.